FDA Pre-IND Meeting Request Granted for VB0004
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The FDA's detailed responses are expected by mid-November. The company aims to finalize its meeting package with the FDA to inform future clinical development stages.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- 2026 Notice of Annual General Meeting & Proxy Form
- 2026 Corporate Governance Statement & Appendix 4G
- Annual Report to shareholders
- Date of 2026 Annual General Meeting
- Change of Director's Interest Notice - MS
Later from Vectus Biosystems
- 2026 AGM Presentations
- Results of 2026 AGM
- Quarterly Activities & Appendix 4C Cash Flow Reports
- Notification regarding unquoted securities - VBS
- Appointment of Prof Tamera Corte as Chief Clinical Advisor
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems